Cleveland Biolabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. SNNLive spoke with Rachel Levine from Cleveland BioLabs, Inc. at The FireRock Conference 2014 in New York City, NY.
Rachel Levine begins with an overview of the company, “We are a microcap, biotech company traded on the NASDAQ and our lead drug is in pre-commercial stage radiation countermeasure for life saving in the event of a disaster or nuclear attack and our intent is to sell this to US and foreign governments. Behind that we have a broad pipeline of novel oncology therapeutics, all of which are currently in phase I trials and we’re expecting some clinical readouts in 2015.”
She goes into more detail about their lead radiation countermeasure drug, “So what we’re talking about here is a one time, one shot rescue therapy from lethal radiation exposure. Projections by the United States government are that if god forbid an event happens, hundreds of thousands of people could be exposed to potentially lethal levels of radiation poisoning, and our drug works with the body's immune system to really induce regeneration and repair of those tissues, and you can give this drug after exposure, which is really when it is needed because there is going to be a mass casualty situation and there's not going to be much infrastructure."
Rachel Levine explains how the FDA grants special accommodations to emergency situational drugs that have not been commercialized yet, “[The FDA] is using a vehicle called Emergency Use Authorization, this is legislation put in place in 2005 and 2006 with project BioShield that enables the government to use unlicensed countermeasures in special circumstances, and in fact that is the very pathway we are pursuing with this drug." For more information, check out their website: www.ClevelandBioLabs.com
© 2017 Stock News Now
Supported by Superior Web Solutions